Amiloidose primária (AL) - Tratamento e prognóstico

Autores

  • Margarida Ascensão Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Helena Figueiredo Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Maria José Nabais Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Paula Pimenta Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Francisco Parente Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Ana Paiva Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • José Feio Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Borges Alexandrino Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Políbio Serra e Silva Serviço de Medicina II dos Hospitais da Universidade de Coimbra

Palavras-chave:

amiloidose primária, AL, tratamen­to, prognóstico, quimioterapia, alfa-interferon

Resumo

A amiloidose primária (AL) é uma entidade que mantém um mau prognóstico, pouco modificado pe­las diversas terapêuticas utilizadas.

Os autores apresentam, com este diagnóstico, sete doentes que foram sujeitos a esquemas terapêuticos dirigidos à AL.

Comentam a sobrevida destes pacientes, a sua rela­ção com os índices de prognóstico e síndromes pre­sentes no início da terapêutica, a evolução sintomáti­ca e funcional com o tratamento e os efeitos secundá­rios apresentados.

Downloads

Não há dados estatísticos.

Referências

Gertz MA, Kyle RA. Primary systemic amyloidosis - a diagnostic primer. Mayo Clinic Proc 1989; 641505-1519.

Hawkins PN, Pepys MB. Amyloidosis. ln Malpas JS, Bergsagel DE, Kyle RA (eds.) Myeloma. Oxford; Oxford University Press. 1995;477-506.

Stone MJ Amyloidosis: a final common pathway for protein deposition in tissues. Blood 1990;75:531-545.

Gertz MA, Kyle RA. Phase II trial of recombinant interferon Alfa-2 in the treatment of primary systemic amyloidosis. Am J Hematol 1993;44:125-128.

Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neural Neurosurg Psychiatry 1996; 60:655-660.

Soloman A, Wciss DT, Pepys MB. Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 1992; 140:629.

Buxhaum J. Mcchanisms of disease: monodonal immunoglobulin deposition. Hematol Oncol Clin North Am 1992; 6:323-345.

Vogelgcsang S, Klipple GL. The many guises of amyloidosis. Postgrad Med 1994; 96:119-127

Parente F. Vieira O, Pimenta P, Alexandrino B, Silva PS. Amiloidose primária - perspectiva terapêutica. Medicina Interna 1995; 2: 97-105

Cohen AS. Amyloidosis. ln Williams (ed). Hematology. New York Me Graw Hill 1990;1148-1157.

Wong CK, Wang WL. Systemic amyloidosis - a report of 19 cases. Dermatology 1994; 189:47-51.

Kyle RA, Greipp PR, O'Fallon M. Primary systemic amyloido­sis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68:220-224.

Kyle RA, Gertz MA. Plimary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.

Gertz MA, Kyle RA. Response of primary hepatic amyloidosis to melphalan and prednison: a case report and review of literature. Mayo Clin Proc 1986;61:218-221.

Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 1994; 24 124-138.

Ge1tz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991;77:257-262

Plehn JF, Cornwell GG. The amyloidoses. ln: Conn RB (ed). Current diagnosis. 8th ed. Philadelphia; W. B. Saunders Com­pany. 1991;785-789.

Ouston M, Skinner M, Anderson l, Cohen AS. Peripheral neuro­pathy as an early marker of AL amyloidosis. Arch Intern Med 1989; 149:358-360

Stone M. Amyloidosis: a final common pathway for the protein deposition in tissues. Blood 1990; 75(3):531-545.

Cohen H, Lessin L, Rurkholder P Resolution of primary amyloidosis during chemotherapy, studies in a patient with nephro­tic syndrome. Ann Intern Med 1975;82:466-473.

Schwartz R, Cohen J, Shrier L. Therapy of primary amyloidosis with melphalan and prednison. Arch Intern Med 1979;139:1144-1147.

Kyle R, Wagoner R, Holley K.Primary systemic amyloidosis, resolution of nephrotic syndrome with melphalan and pred­nison. Arch Intern Med 1982;146:1445-1447.

Galton DA, Babapulle FB. The management of myelomatosis. Eur J Haematol 1987; 39:385-398.

Gertz MA, Kyle RA. Successful treatment of primary amyloidosis (letter). 'The authors reply. Mayo Clin Pare 1986; 61:835-836.

Hachulla E, Deveaux M, Duquesnoy B, Marchandise X. Carto­ graphie de l'amylose par scintigraphie au composant sérique amyloide P marqué à l'iode 123: mythe ou réalité? Rev Med Interne 1994; 15:238-239.

Hawkins PN. Diagnosis and monitoring of amyloidosis. Baillie­res Clin Rheumatol 1994; 8:635-659.

Maulin L, Hachulla E, Facon T et ai. Évaluation de l'amylose primitive (AL) par scintigraphie au composantsérique amyloide P: du diagnostic au prognostic. Rev Med Interne 1993; 14:%2.

Hawkins PN, Richardson S, MacSweeney JE et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for tu mover and regression. QJ Med 1993; 86:365-374.

Hachulla E, Deveaux M, Duquesnoy B, Marchandise X. Scinti­graphie au composant amyloide P marqué à l'iode 123: une nouvelle méthode d'évaluation de l'amylose. La Presse Médi­cale 1994; 23:348

Kyle RA. Primary systemic amyloidosis.J lntMed 1992; 232:523-524.

Benson MD. Familial amyloidosis. J lnt Med 1992; 232:525-527.

Kyle AR, Gertz MA. Amyloidosis. ln: Lichtenstein LM, Fauci AS. Current therapy in allergy, immunology and rheumatology, 4th ed, Baltimore: B.C Decker 1992;207-210.

Kyle R, Greipp P, Garton J et al. Primary systemic amyloidosis comparison of melphalan/ prednison versus colchicine. Am J Med 1985; 79:708-718

Lévy Y, Deprez D, Sobel A. Traitment de l'amylose AL sans myélome. Ann Med Intern 1988;139:190-193.

Fritz D, Luggen M, Hess E. Unusual longevity in a primary systemic amyloidosis: a 19 year survivor. Am J Med 1989; 86:245-248.

Cohen A, Rubinow A, Anderson J et al. Survival of patients with primary (AL) amyloidosis colchicine treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 1987; 82:1182-1190

Gilman AG, Rali TW, Nies AS Taylor P (eds). Goodman & Gilman The pharmacological basis of therapeutics, 8th ed, New York; Pergamon Press 1990.

Ravid M, Chen B, Bernheim J, Kedar I. Ascorbic acid-induced regression of amyloidosis in experimental animais. J Exp Path 1985; 66:137-141.

Cohen AS, Jones LA. Advances in amyloidosis. Curr Opin Rheu­matol 1993; 5:62-76.

Laraki R. L'amylose cardiaque - revue générale. Rev Med Inter­ne 1994; 15:257-267.

Fielder K, Durie B. Primary amyloidosis associated with multi­ple myeloma: predictors of successful therapy. Am J Med 1986; 80:413-418.

Ficheiros Adicionais

Publicado

30-09-1997

Como Citar

1.
Ascensão M, Figueiredo H, Nabais MJ, Pimenta P, Parente F, Paiva A, Feio J, Alexandrino B, Serra e Silva P. Amiloidose primária (AL) - Tratamento e prognóstico. RPMI [Internet]. 30 de Setembro de 1997 [citado 1 de Março de 2024];4(3):150-5. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/2224

Edição

Secção

Artigos Originais

Artigos mais lidos do(s) mesmo(s) autor(es)

1 2 3 4 > >>